Robust LC–MS/MS methods for analysis of heparan sulfate levels in CSF and brain for application in studies of MPS IIIA

Accumulation of heparan sulfate (HS) is associated with the neurodegenerative disorder Mucopolysaccharidosis type IIIA (MPS IIIA). Here, we compare HS levels in brain and cerebrospinal fluid (CSF) of MPS IIIA mice after treatment with a chemically modified sulfamidase (CM-rhSulfamidase). Two LC–MS/M...

Full description

Saved in:
Bibliographic Details
Published in:Bioanalysis 2019-08, Vol.11 (15), p.1389-1403
Main Authors: Makower, Åsa, Arnelöf, Erik, Andersson, Tommy, Edlund, Per-Olof, Gustavsson, Susanne, Janson, Juliette, Gelius, Stefan Svensson, Tjernberg, Agneta
Format: Article
Language:English
Subjects:
3-methyl-1-phenyl-2-pyrazolino-5-one derivatization
Acids
Biomarkers
Cerebrospinal fluid
enzyme replacement therapy
Enzymes
glycosaminoglycans
Heparan sulfate
heparinase
LC–MS/MS
lysosomal storage
Metabolites
Methods
Mucopolysaccharidosis
multiple reaction monitoring
Mutation
Neurodegenerative diseases
Spleen
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Accumulation of heparan sulfate (HS) is associated with the neurodegenerative disorder Mucopolysaccharidosis type IIIA (MPS IIIA). Here, we compare HS levels in brain and cerebrospinal fluid (CSF) of MPS IIIA mice after treatment with a chemically modified sulfamidase (CM-rhSulfamidase). Two LC–MS/MS methods were adapted from literature methodology, one to measure HS metabolites (HS ), the other to measure digests of HS after heparinase treatment (HS ). The HS and HS methods showed similar relative reduction of HS in brain after CM-rhSulfamidase administration to MPS IIIA mice and the reduction was reflected also in CSF. The results of the two methods correlated and therefore the HS method can be used in clinical studies to determine HS levels in CSF from patients with MPS IIIA.
ISSN:1757-6180
1757-6199
DOI:10.4155/bio-2019-0095